Intelligence Feed event · Capital · 2026-09-25

    ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per Share

    Question

    ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per Share

    Direct answer

    Late-stage clinical biotechnology firm ADARx Pharmaceuticals completed pricing of its initial public offering on September 24, 2026, raising $446.3 million in gross proceeds. The offering was upsized to 26.25 million shares priced at $17.00 each. The stock is set to commence trading on the Nasdaq Global Market on September 25 under ticker ADRX, providing fresh liquidity sentiment for mid-cap biotech ECM.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per Share”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-ipo-at-17-per-share-20990b

    CAPITAL
    ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per Share
    Late-stage clinical biotechnology firm ADARx Pharmaceuticals completed pricing of its initial public offering on September 24, 2026, raising $446.3 million in gross proceeds. The offering was upsized to 26.25 million shares priced at $17.00 each. The stock is set to commence trading on the Nasdaq Global Market on September 25 under ticker ADRX, providing fresh liquidity sentiment for mid-cap biotech ECM.
    ADRX
    Impact
    69
    SEP 25
    SIG
    95%
    ADRX
    ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per Share
    Late-stage clinical biotechnology firm ADARx Pharmaceuticals completed pricing of its initial public offering on September 24, 2026, raising $446.3 million in gross proceeds. The offering was upsized to 26.25 million shares priced at $17.00 each. The stock is set to commence trading on the Nasdaq Global Market on September 25 under ticker ADRX, providing fresh liquidity sentiment for mid-cap biotech ECM.
    → Direct equity issuance injects $446.3M gross cash onto ADRX balance sheet to fund clinical-stage siRNA pipelines.
    Impact
    Late-stage clinical biotechnology firm ADARx Pharmaceuticals completed pricing of its initial public offering on September 24, 2026, raising $446.3 million in gross proceeds. The offering was upsized to 26.25 million shares priced at $17.00 each. The stock is set to commence trading on the Nasdaq Global Market on September 25 under ticker ADRX, providing fresh liquidity sentiment for mid-cap biotech ECM.
    Affected
    ADRX
    Transmission
    Direct equity issuance injects $446.3M gross cash onto ADRX balance sheet to fund clinical-stage siRNA pipelines.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    ADRXWatch19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month